Kenvue Inc. (KVUE)
(Delayed Data from NYSE)
$21.99 USD
-0.17 (-0.77%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $21.99 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.99 USD
-0.17 (-0.77%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $21.99 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth D Momentum D VGM
Zacks News
Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?
by Zacks Equity Research
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.
Will Kenvue (KVUE) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPYD
J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?
by Kinjel Shah
We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.
Should SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SDY
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYD
Is SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SDY
The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly
by Zacks Equity Research
Johnson & Johnson, Kenvue and Eli Lilly are included in this Analyst Blog.
J&J's Stock Up 12.8% in 3 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.
International Flavors (IFF) Q2 Earnings Top on Higher Volumes
by Zacks Equity Research
International Flavors (IFF) reports volume growth in high-single digits in second-quarter 2024. The company expects 2024 sales to be in the range of $11.1-$11.3 billion.
Compared to Estimates, Kenvue (KVUE) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Kenvue (KVUE) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Kenvue (KVUE) delivered earnings and revenue surprises of 14.29% and 1.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?
by Kinjel Shah
Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
by Kinjel Shah
J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.
J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Kinjel Shah
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
by Kinjel Shah
A new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However, those who already own the stock may stay invested as the company is generating decent sales growth.
Want Better Returns? Don?t Ignore These 2 Consumer Staples Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Stock Market News for May 8, 2024
by Zacks Equity Research
Wall Street ended mixed on Tuesday as investors eagerly awaited signals from the Federal Reserve regarding potential interest rate cuts.
Why Kenvue (KVUE) Could Beat Earnings Estimates Again
by Zacks Equity Research
Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Consumer Staples Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Key Takeaways From JNJ's (JNJ) Q4 Earnings Presentation
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.
J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales
by Zacks Equity Research
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.
J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
Company News for Dec 20, 2023
by Zacks Equity Research
Companies in The News Are: BA, DLAKY, KVUE, INTC, SHEL